KMDA
Kamada Ltd.
Price Chart
Latest Quote
$7.18
+0.04 (+0.63%)
Current Price
| Previous Close | $7.13 |
| Open | $7.13 |
| Day High | $7.19 |
| Day Low | $7.11 |
| Volume | 27,864 |
Stock Information
| Quarterly Dividend / Yield | $0.25 / 3.51% |
| Shares Outstanding | 57.69M |
| Quarterly Dividend Yield | 3.51% |
| Quarterly Dividend | $0.25 |
| Total Debt | $11.64M |
| Cash Equivalents | $73.15M |
| Revenue | $181.68M |
| Net Income | $20.37M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $414.24M |
| P/E Ratio | 20.51 |
| EPS (TTM) | $0.35 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $352.68M |
| Sales | $181.68M |
| Income | $20.37M |
| Book/sh | $4.50 |
| Cash/sh | $1.27 |
| Employees | 462 |
Financial Ratios
| Quick Ratio | 1.90 |
| Current Ratio | 3.33 |
| Debt/Eq | 4.49 |
| EPS Growth TTM | 4.20% |
Returns & Margins
| ROA | 4.19% |
| ROE | 7.97% |
| Gross Margin | 41.16% |
| Operating Margin | 15.37% |
| Profit Margin | 11.21% |
Ownership
| Insider Ownership | 7.20% |
| Institutional Ownership | 48.56% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 11.71 |
| PEG | 0.70 |
| P/S | 2.28 |
| P/B | 1.60 |
Analyst Data
| Recommendation | none |
| Target Price | $13.00 |
Technical Indicators
| SMA20 | $7.38 |
| SMA50 | $7.84 |
| SMA200 | $7.52 |
| RSI | 40.38 |
| ATR | 0.1621 |
| Shares Float | 31.45M |
| Short Float | 0.43% |
| Short Ratio | 2.43 |
| Volatility | 0.15 |
| Rel Volume | 0.69 |
Performance History
| Week | -1.10% |
| Month | -9.69% |
| Quarter | -12.44% |
| 6 Months | +4.63% |
| YTD | +5.23% |
| Year | -6.95% |
| 3 Years | +43.58% |
| 5 Years | +31.65% |
| 10 Years | +110.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $7.18 | 27,864 |
| 2026-06-24 | $7.14 | 17,300 |
| 2026-06-23 | $7.13 | 51,900 |
| 2026-06-22 | $7.19 | 70,400 |
| 2026-06-18 | $7.31 | 25,100 |
| 2026-06-17 | $7.26 | 21,700 |
| 2026-06-16 | $7.46 | 86,900 |
| 2026-06-15 | $7.46 | 18,600 |
| 2026-06-12 | $7.44 | 25,800 |
| 2026-06-11 | $7.44 | 25,800 |
| 2026-06-10 | $7.21 | 30,400 |
| 2026-06-09 | $7.24 | 19,600 |
| 2026-06-08 | $7.24 | 70,400 |
| 2026-06-05 | $7.17 | 46,800 |
| 2026-06-04 | $7.38 | 51,300 |
| 2026-06-03 | $7.39 | 59,700 |
| 2026-06-02 | $7.51 | 49,800 |
| 2026-06-01 | $7.70 | 50,100 |
| 2026-05-29 | $7.81 | 35,400 |
| 2026-05-28 | $7.86 | 26,200 |
| 2026-05-27 | $7.98 | 49,900 |
| 2026-05-26 | $7.95 | 92,500 |
About Kamada Ltd.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
đ° Latest News
Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Growth Amid Shipment Delays
GuruFocus.com âĸ 2026-05-13T23:01:35ZKamada (KMDA) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-13T18:57:34Z
Kamada Ltd. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T16:48:15Z
Kamada Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T16:07:23Z
Kamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks âĸ 2026-05-13T13:30:04Z
Kamada Q1 2026 Earnings Call: Complete Transcript
Benzinga âĸ 2026-05-13T12:59:57Z
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-13T12:15:02Z
Earnings Scheduled For May 13, 2026
Benzinga âĸ 2026-05-13T11:11:36Z
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-12T12:40:04Z
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates
Zacks âĸ 2026-05-12T00:05:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $92,473,000 | $80,474,000 | $77,440,000 | $73,510,000 |
| Cost Of Revenue | $104,053,000 | $90,986,000 | $87,029,000 | $82,636,000 |
| Total Revenue | $180,460,000 | $160,953,000 | $142,519,000 | $129,339,000 |
| Operating Revenue | $180,460,000 | $160,953,000 | $142,519,000 | $129,339,000 |
| Expenses | ||||
| Interest Expense | $864,000 | $660,000 | $1,298,000 | $914,000 |
| Total Expenses | $154,227,000 | $140,902,000 | $132,455,000 | $124,807,000 |
| Other Income Expense | $-3,823,000 | $-8,175,000 | $-925,000 | $-5,968,000 |
| Other Non Operating Income Expenses | $-2,652,000 | $-8,081,000 | $-980,000 | $-6,266,000 |
| Net Non Operating Interest Income Expense | $1,057,000 | $1,458,000 | $-710,000 | $-823,000 |
| Interest Expense Non Operating | $864,000 | $660,000 | $1,298,000 | $914,000 |
| Operating Expense | $50,174,000 | $49,916,000 | $45,426,000 | $42,171,000 |
| Selling And Marketing Expense | $9,732,000 | $10,427,000 | $9,196,000 | $9,181,000 |
| General And Administrative Expense | $24,109,000 | $20,407,000 | $18,253,000 | $15,877,000 |
| Other Operating Expenses | - | $601,000 | $919,000 | $912,000 |
| Total Other Finance Cost | - | - | $980,000 | $6,266,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Net Interest Income | $1,057,000 | $1,458,000 | $-710,000 | $-823,000 |
| Interest Income | $1,921,000 | $2,118,000 | $588,000 | $91,000 |
| Normalized Income | $21,205,877 | $14,534,380 | $8,229,946 | $-2,550,460 |
| Net Income From Continuing And Discontinued Operation | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Total Operating Income As Reported | $26,233,000 | $20,051,000 | $10,064,000 | $4,532,000 |
| Net Income Common Stockholders | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Net Income | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Net Income Including Noncontrolling Interests | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Net Income Continuous Operations | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Pretax Income | $23,467,000 | $13,334,000 | $8,429,000 | $-2,259,000 |
| Interest Income Non Operating | $1,921,000 | $2,118,000 | $588,000 | $91,000 |
| Operating Income | $26,233,000 | $20,051,000 | $10,064,000 | $4,532,000 |
| Depreciation Amortization Depletion Income Statement | $3,338,000 | $3,296,000 | $3,125,000 | $3,029,000 |
| Depreciation And Amortization In Income Statement | $3,338,000 | $3,296,000 | $3,125,000 | $3,029,000 |
| Gross Profit | $76,407,000 | $69,967,000 | $55,490,000 | $46,703,000 |
| Per Share | ||||
| Diluted EPS | $0.35 | $0.25 | $0.15 | $-0.05 |
| Basic EPS | $0.35 | $0.25 | $0.17 | $-0.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $-163,123 | $-21,620 | $946 | $68,540 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $40,420,000 | $27,896,000 | $22,386,000 | $10,512,000 |
| Total Unusual Items | $-1,171,000 | $-94,000 | $55,000 | $298,000 |
| Total Unusual Items Excluding Goodwill | $-1,171,000 | $-94,000 | $55,000 | $298,000 |
| Reconciled Depreciation | $14,918,000 | $13,808,000 | $12,714,000 | $12,155,000 |
| EBITDA (Bullshit earnings) | $39,249,000 | $27,802,000 | $22,441,000 | $10,810,000 |
| EBIT | $24,331,000 | $13,994,000 | $9,727,000 | $-1,345,000 |
| Diluted Average Shares | $57,708,571 | $57,848,000 | $53,675,514 | $46,420,000 |
| Basic Average Shares | $57,708,571 | $57,848,000 | $48,830,479 | $46,420,000 |
| Diluted NI Availto Com Stockholders | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Tax Provision | $3,269,000 | $-1,128,000 | $145,000 | $62,000 |
| Gain On Sale Of Security | $-1,171,000 | $-94,000 | $55,000 | $298,000 |
| Research And Development | $12,995,000 | $15,185,000 | $13,933,000 | $13,172,000 |
| Selling General And Administration | $33,841,000 | $30,834,000 | $27,449,000 | $25,058,000 |
| Other Gand A | $8,089,000 | $5,901,000 | $5,160,000 | $6,076,000 |
| Insurance And Claims | $1,387,000 | $1,171,000 | $1,566,000 | - |
| Salaries And Wages | $14,633,000 | $13,335,000 | $11,527,000 | $9,801,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $142,661,000 | $127,291,000 | $104,066,000 | $29,011,000 |
| Total Assets | $378,710,000 | $372,255,000 | $354,907,000 | $322,379,000 |
| Total Non Current Assets | $185,635,000 | $187,908,000 | $184,945,000 | $183,374,000 |
| Other Non Current Assets | $30,313,000 | - | $-1,000 | - |
| Non Current Prepaid Assets | $1,415,000 | $1,366,000 | $510,000 | $63,000 |
| Non Current Deferred Assets | $0 | $488,000 | $0 | - |
| Non Current Deferred Taxes Assets | $0 | $488,000 | $0 | - |
| Non Current Accounts Receivable | $7,544,000 | $8,019,000 | $8,495,000 | $7,577,000 |
| Goodwill And Other Intangible Assets | $126,409,000 | $132,173,000 | $139,955,000 | $147,009,000 |
| Other Intangible Assets | $96,096,000 | $101,860,000 | $109,642,000 | $116,696,000 |
| Current Assets | $193,075,000 | $184,347,000 | $169,962,000 | $139,005,000 |
| Hedging Assets Current | $197,000 | $49,000 | $149,000 | $0 |
| Prepaid Assets | $3,623,000 | $3,847,000 | $4,405,000 | $3,875,000 |
| Inventory | $84,943,000 | $78,819,000 | $88,479,000 | $72,517,000 |
| Receivables | $28,843,000 | $23,197,000 | $21,288,000 | $28,355,000 |
| Other Receivables | $1,836,000 | $1,809,000 | $1,562,000 | $1,227,000 |
| Accounts Receivable | $27,007,000 | $21,388,000 | $19,726,000 | $27,128,000 |
| Allowance For Doubtful Accounts Receivable | $0 | $0 | $0 | $0 |
| Gross Accounts Receivable | $27,007,000 | $21,388,000 | $19,726,000 | $27,128,000 |
| Cash Cash Equivalents And Short Term Investments | $75,469,000 | $78,435,000 | $55,641,000 | $34,258,000 |
| Cash And Cash Equivalents | $75,469,000 | $78,435,000 | $55,641,000 | $34,258,000 |
| Cash Equivalents | $37,246,000 | $55,305,000 | $15,011,000 | $2,847,000 |
| Cash Financial | $38,223,000 | $23,130,000 | $40,630,000 | $31,411,000 |
| Debt | ||||
| Total Debt | $11,561,000 | $11,062,000 | $8,822,000 | $20,600,000 |
| Long Term Debt And Capital Lease Obligation | $9,440,000 | $9,431,000 | $7,438,000 | $15,140,000 |
| Current Debt And Capital Lease Obligation | $2,121,000 | $1,631,000 | $1,384,000 | $5,460,000 |
| Long Term Debt | - | - | - | $12,963,000 |
| Current Debt | - | - | - | $4,444,000 |
| Other Current Borrowings | - | - | - | $4,444,000 |
| Net Debt | - | - | - | - |
| Liabilities | ||||
| Minimum Pension Liabilities | $385,000 | $364,000 | $275,000 | $348,000 |
| Total Liabilities Net Minority Interest | $109,640,000 | $112,791,000 | $110,886,000 | $146,359,000 |
| Total Non Current Liabilities Net Minority Interest | $62,246,000 | $63,402,000 | $61,293,000 | $70,654,000 |
| Other Non Current Liabilities | $50,485,000 | $53,462,000 | $53,234,000 | $54,842,000 |
| Non Current Deferred Liabilities | $1,651,000 | $0 | - | $0 |
| Non Current Deferred Taxes Liabilities | $1,651,000 | $0 | - | - |
| Current Liabilities | $47,394,000 | $49,389,000 | $49,593,000 | $75,705,000 |
| Other Current Liabilities | $9,923,000 | $10,181,000 | $14,996,000 | $29,800,000 |
| Current Deferred Liabilities | $0 | $171,000 | $325,000 | $236,000 |
| Payables And Accrued Expenses | $25,083,000 | $28,188,000 | $25,346,000 | $33,526,000 |
| Payables | $23,242,000 | $27,735,000 | $24,804,000 | $32,917,000 |
| Accounts Payable | $23,242,000 | $27,735,000 | $24,804,000 | $32,917,000 |
| Equity | ||||
| Common Stock Equity | $269,070,000 | $259,464,000 | $244,021,000 | $176,020,000 |
| Total Equity Gross Minority Interest | $269,070,000 | $259,464,000 | $244,021,000 | $176,020,000 |
| Stockholders Equity | $269,070,000 | $259,464,000 | $244,021,000 | $176,020,000 |
| Other Equity Interest | $5,711,000 | $6,316,000 | $6,427,000 | $5,505,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,928,000 | $-3,075,000 | $-3,075,000 | $-3,230,000 |
| Other Equity Adjustments | $177,000 | $51,000 | $140,000 | $-88,000 |
| Retained Earnings | $-17,074,000 | $-25,738,000 | $-40,200,000 | $-48,484,000 |
| Other | ||||
| Ordinary Shares Number | $57,686,056 | $57,505,031 | $57,479,528 | $44,832,843 |
| Share Issued | $57,686,056 | $57,505,031 | $57,479,528 | $44,832,843 |
| Tangible Book Value | $142,661,000 | $127,291,000 | $104,066,000 | $29,011,000 |
| Invested Capital | $269,070,000 | $259,464,000 | $244,021,000 | $193,427,000 |
| Working Capital | $145,681,000 | $134,958,000 | $120,369,000 | $63,300,000 |
| Capital Lease Obligations | $11,561,000 | $11,062,000 | $8,822,000 | $3,193,000 |
| Total Capitalization | $269,070,000 | $259,464,000 | $244,021,000 | $188,983,000 |
| Foreign Currency Translation Adjustments | $-3,490,000 | $-3,490,000 | $-3,490,000 | $-3,490,000 |
| Additional Paid In Capital | $268,283,000 | $266,933,000 | $265,848,000 | $210,495,000 |
| Capital Stock | $15,078,000 | $15,028,000 | $15,021,000 | $11,734,000 |
| Common Stock | $15,078,000 | $15,028,000 | $15,021,000 | $11,734,000 |
| Employee Benefits | $670,000 | $509,000 | $621,000 | $672,000 |
| Long Term Capital Lease Obligation | $9,440,000 | $9,431,000 | $7,438,000 | $2,177,000 |
| Current Deferred Revenue | $0 | $171,000 | $325,000 | $236,000 |
| Current Capital Lease Obligation | $2,121,000 | $1,631,000 | $1,384,000 | $1,016,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,267,000 | $9,218,000 | $7,542,000 | $6,683,000 |
| Current Accrued Expenses | $1,841,000 | $453,000 | $542,000 | $609,000 |
| Goodwill | $30,313,000 | $30,313,000 | $30,313,000 | $30,313,000 |
| Net PPE | $50,267,000 | $45,862,000 | $35,985,000 | $28,725,000 |
| Accumulated Depreciation | $-70,922,000 | $-64,864,000 | $-60,410,000 | $-56,210,000 |
| Gross PPE | $121,189,000 | $110,726,000 | $96,395,000 | $84,935,000 |
| Leases | $10,421,000 | $9,044,000 | $3,093,000 | $1,566,000 |
| Machinery Furniture Equipment | $61,880,000 | $56,111,000 | $50,897,000 | $46,540,000 |
| Buildings And Improvements | $7,594,000 | $8,232,000 | $6,363,000 | $1,732,000 |
| Land And Improvements | $41,294,000 | $37,324,000 | $36,041,000 | $35,090,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $8,143,000 | $9,749,000 | $11,021,000 | $8,486,000 |
| Finished Goods | $35,422,000 | $29,368,000 | $42,526,000 | $30,429,000 |
| Work In Process | $7,033,000 | $9,165,000 | $6,653,000 | $12,276,000 |
| Raw Materials | $34,345,000 | $30,537,000 | $28,279,000 | $21,326,000 |
| Other Properties | - | $15,000 | $1,000 | $7,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
| Other Short Term Investments | - | - | - | - |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $15,644,000 | $36,854,000 | $-1,535,000 | $24,802,000 |
| Operating Activities | ||||
| Operating Cash Flow | $25,490,000 | $47,594,000 | $4,315,000 | $28,586,000 |
| Cash Flow From Continuing Operating Activities | $25,490,000 | $47,594,000 | $4,315,000 | $28,586,000 |
| Operating Gains Losses | $175,000 | $63,000 | $-130,000 | $-111,000 |
| Investing Activities | ||||
| Capital Expenditure | $-9,846,000 | $-10,740,000 | $-5,850,000 | $-3,784,000 |
| Investing Cash Flow | $-9,838,000 | $-10,739,000 | $-5,843,000 | $-3,784,000 |
| Cash Flow From Continuing Investing Activities | $-9,838,000 | $-10,739,000 | $-5,843,000 | $-3,784,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $58,231,000 | $0 |
| Financing Cash Flow | $-18,345,000 | $-13,911,000 | $22,678,000 | $-9,343,000 |
| Cash Flow From Continuing Financing Activities | $-18,345,000 | $-13,911,000 | $22,678,000 | $-9,343,000 |
| Net Other Financing Charges | $-5,889,000 | $-12,667,000 | $-17,300,000 | $-5,626,000 |
| Cash Dividends Paid | $-11,534,000 | $0 | $0 | - |
| Common Stock Dividend Paid | $-11,534,000 | $0 | $0 | - |
| Net Common Stock Issuance | $0 | $0 | $58,231,000 | $0 |
| Common Stock Issuance | $0 | $0 | $58,231,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-972,000 | $-1,251,000 | $-18,257,000 | $-3,726,000 |
| End Cash Position | $75,469,000 | $78,435,000 | $55,641,000 | $34,258,000 |
| Beginning Cash Position | $78,435,000 | $55,641,000 | $34,258,000 | $18,587,000 |
| Effect Of Exchange Rate Changes | $-273,000 | $-150,000 | $233,000 | $212,000 |
| Changes In Cash | $-2,693,000 | $22,944,000 | $21,150,000 | $15,459,000 |
| Proceeds From Stock Option Exercised | $50,000 | $7,000 | $4,000 | $9,000 |
| Net Issuance Payments Of Debt | $-972,000 | $-1,251,000 | $-18,257,000 | $-3,726,000 |
| Net Long Term Debt Issuance | $-972,000 | $-1,251,000 | $-18,257,000 | $-3,726,000 |
| Long Term Debt Payments | $-972,000 | $-1,251,000 | $-18,257,000 | $-3,726,000 |
| Net PPE Purchase And Sale | $-9,838,000 | $-10,739,000 | $-5,843,000 | $-3,784,000 |
| Sale Of PPE | $8,000 | $1,000 | $7,000 | $0 |
| Purchase Of PPE | $-9,846,000 | $-10,740,000 | $-5,850,000 | $-3,784,000 |
| Taxes Refund Paid | $-56,000 | $-139,000 | $-217,000 | $-36,000 |
| Interest Received Cfo | $1,921,000 | $2,118,000 | $0 | $97,000 |
| Interest Paid Cfo | $-864,000 | $-594,000 | $-1,228,000 | $-853,000 |
| Change In Working Capital | $-17,682,000 | $11,413,000 | $-18,202,000 | $11,649,000 |
| Change In Other Working Capital | $-171,000 | $23,000 | $113,000 | $-20,000 |
| Change In Payables And Accrued Expense | $-5,920,000 | $2,639,000 | $-8,120,000 | $7,345,000 |
| Change In Payable | $-5,920,000 | $2,639,000 | $-8,120,000 | $7,345,000 |
| Change In Account Payable | $-6,870,000 | $1,226,000 | $-8,885,000 | $7,055,000 |
| Change In Inventory | $-6,124,000 | $9,659,000 | $-19,694,000 | $-1,361,000 |
| Change In Receivables | $-5,467,000 | $-908,000 | $9,499,000 | $5,685,000 |
| Changes In Account Receivables | $-5,407,000 | $-1,977,000 | $7,835,000 | $7,603,000 |
| Other Non Cash Items | $2,766,000 | $6,717,000 | $1,635,000 | $6,791,000 |
| Stock Based Compensation | $845,000 | $874,000 | $1,314,000 | $1,153,000 |
| Deferred Tax | $3,269,000 | $-1,128,000 | $145,000 | $62,000 |
| Deferred Income Tax | $3,269,000 | $-1,128,000 | $145,000 | $62,000 |
| Depreciation Amortization Depletion | $14,918,000 | $13,808,000 | $12,714,000 | $12,155,000 |
| Depreciation And Amortization | $14,918,000 | $13,808,000 | $12,714,000 | $12,155,000 |
| Pension And Employee Benefit Expense | $183,000 | $52,000 | $-125,000 | $-111,000 |
| Gain Loss On Sale Of PPE | $-8,000 | $11,000 | $-5,000 | $0 |
| Net Income From Continuing Operations | $20,198,000 | $14,462,000 | $8,284,000 | $-2,321,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Net Investment Purchase And Sale | - | - | $0 | $0 |
| Depreciation | - | - | $12,714,000 | $12,155,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Sale Of Investment | - | - | - | - |
Fetched: 2026-06-25